In conclusion, since TLR4 and AGER expressions are predominantly described in IBC tumors compared to other clinical presentations of BC, understanding IBC biology will help to improve clinical therapeutic outcomes for these patients. Here, TLR4 is linked to inflammatory breast carcinoma.